MBX Biosciences (MBX) vs Pharvaris N.V. (PHVS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
MBX Biosciences (MBX) has outperformed Pharvaris N.V. (PHVS) over the past year, gaining 83.0% versus a gain of 26.0%. MBX Biosciences is the larger company by market cap ($2.46 billion vs $2.21 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MBX | PHVS |
|---|---|---|
| Share price | $49.55 | $31.28 |
| Market cap | $2.46B | $2.21B |
| 1-day change | -7.23% | -1.20% |
| YTD return | +57.10% | +12.72% |
| 1-year return | +82.98% | +25.98% |
| 5-year return | — | +131.28% |
| EPS (TTM) | $-3.03 | $-3.13 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-87.00M | $-25.99M |
| 52-week high | $72.64 | $43.25 |
| 52-week low | $26.14 | $23.15 |
| Distance from 52-week high | -31.79% | -27.68% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +91.91% | +86.29% |
| Average volume | 532.80K | 756.20K |
| Shares outstanding | 49.66M | 70.79M |
| Employees | 63 | 168 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MBX has outperformed PHVS by 57.0 percentage points over the past year.
About MBX Biosciences
MBX stock →MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism.
Health Care · Biotechnology: Pharmaceutical Preparations · 63 employees
About Pharvaris N.V.
PHVS stock →Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant.
Health Care · Biotechnology: Pharmaceutical Preparations · 168 employees
MBX vs PHVS FAQ
Which is bigger, MBX Biosciences or Pharvaris N.V.?
MBX Biosciences (MBX) is larger, with a market capitalization of $2.46B compared with $2.21B for Pharvaris N.V. (PHVS).
Which stock has performed better over the past year, MBX or PHVS?
MBX returned +82.98% over the past 12 months, compared with +25.98% for PHVS (price return, excluding dividends). Past performance does not predict future results.
Are MBX Biosciences and Pharvaris N.V. in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.